Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Furmonertinib in Combination with Anlotinib and Chemotherapy As Neoadjuvant Treatment for Resectable, Stage II-III EGFR-Mutated Non-Small Cell Lung Cancer: a Single-Arm, Open-Label, Phase II Clinical Trial

NCT06585644 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT06585644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06585644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Furmonertinib in Combination with Anlotinib and Chemotherapy As Neoadjuvant Treatment for Resectable, Stage II-III EGFR-Mutated Non-Small Cell Lung Cancer: a Single-Arm, Open-Label, Phase II Clinical Trial
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2024
Completion date
June 1, 2030
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)